Revision per component

Cemented primary THA – overall revision
Uncemented primary THA – overall revsion
Cemented primary THA – major revision
Uncemented primary THA – major revision
Bone cement THA
THA by ODEP 5A or higher acetabulum
THA by ODEP 5A or higher femur
THA by cemented material acetabulum
THA by uncemented material inlay
THA by cemented material femur
THA by uncemented material femur
THA by modularity

Hip » Survival » Revision per component » Cemented primary THA – overall revision

TABLE Cumulative revision percentages of cemented primary total hip arthroplasties by prosthesis component combination of patients who underwent a THA for osteoarthritis in the Netherlands in 2007-2021 (n=82,092)

					Type of revision (n)					Cumulative revision percentage (95% CI)
Femur component	Acetabulum component	Total primary THAs (n)	Median (IQR) age (yr)	Total revision arthroplasties (n)	Total hip (complete revision)	Only femur component	Only acetabulum component	Only femoral head/inlay	Missing/ unknown	1yr	3yr	5yr	7yr	10yr	13yr
All cemented THAs for osteoarthritis		82,092	76 (71-81)	2,345	461	241	958	645	40	1.3 (1.2-1.4)	2.0 (1.9-2.1)	2.6 (2.4-2.7)	3.0 (2.9-3.1)	3.7 (3.6-3.9)	4.6 (4.3-4.9)
Lubinus SPII	IP Cup	14,118	76 (72-81)	362	54	46	161	96	5	1.1 (0.9-1.3)	2.0 (1.7-2.2)	2.5 (2.2-2.8)	2.8 (2.5-3.1)	3.2 (2.8-3.5)	4.0 (3.4-4.7)
Original ME Muller	Muller low profile Durasul	8,498	75 (70-80)	225	28	5	49	140	3	1.8 (1.5-2.1)	2.3 (1.9-2.6)	2.7 (2.4-3.1)	3.0 (2.6-3.5)	3.7 (3.1-4.3)	3.9 (3.2-4.7)
Original ME Muller	Muller low profile	6,324	77 (73-81)	176	24	2	103	41	6	1.4 (1.1-1.7)	2.4 (2.0-2.8)	2.7 (2.3-3.1)	3.1 (2.6-3.5)	3.1 (2.6-3.5)	3.3 (2.8-3.9)
Lubinus SPII	FAL Cup	5,760	75 (70-80)	186	42	11	70	58	5	1.9 (1.5-2.2)	2.5 (2.1-2.9)	3.1 (2.7-3.6)	3.8 (3.2-4.4)	4.5 (3.7-5.2)	5.1 (4.0-6.2)
Spectron EF	Reflection All Poly XLPE	4,878	77 (73-81)	112	37	13	40	22	0	0.6 (0.4-0.9)	1.4 (1.1-1.8)	1.8 (1.4-2.2)	2.6 (2.1-3.0)	2.8 (2.3-3.4)	3.0 (2.4-3.6)
Exeter	Exeter Rimfit X3	4,664	75 (69-80)	99	24	20	22	33	0	1.4 (1.0-1.7)	1.9 (1.5-2.3)	2.4 (1.9-2.9)	2.4 (1.9-2.9)	2.6 (2.0-3.1)	n.a.
Stanmore	Stanmore	3,374	75 (70-80)	73	25	2	39	5	2	0.7 (0.4-1.0)	1.4 (1.0-1.8)	1.9 (1.4-2.3)	2.0 (1.5-2.5)	2.5 (1.9-3.1)	2.7 (2.0-3.4)
Exeter	Exeter Contemporary Hooded	2,827*	77 (72-81)	95	22	20	36	14	3	1.2 (0.8-1.6)	1.7 (1.2-2.2)	2.3 (1.7-2.9)	2.9 (2.3-3.6)	4.2 (3.3-5.1)	4.7 (3.6-5.8)
Lubinus SPII	SHP	2,506*	75 (71-80)	45	9	3	32	1	0	0.2 (0.0-0.4)	0.7 (0.3-1.0)	1.0 (0.6-1.3)	1.7 (1.2-2.2)	2.0 (1.4-2.6)	2.1 (1.5-2.7)
Exeter	Exeter	2,447*	73 (68-79)	142	23	14	70	31	4	2.8 (2.1-3.4)	3.6 (2.8-4.3)	4.1 (3.3-4.9)	4.9 (4.0-5.7)	6.2 (5.2-7.3)	7.0 (5.8-8.2)
Exeter	Exeter Contemporary Flanged	2,436	75 (67-80)	77	17	9	40	9	2	0.8 (0.4-1.1)	1.4 (0.9-1.9)	2.0 (1.4-2.6)	2.3 (1.7-3.0)	3.3 (2.5-4.2)	5.0 (3.6-6.3)
Stanmore	SHP	2,097*	75 (71-79)	115	39	5	60	10	1	1.6 (1.0-2.1)	3.1 (2.3-3.8)	4.0 (3.2-4.9)	4.8 (3.8-5.7)	5.8 (4.7-6.9)	8.1 (6.4-9.9)
CCA stem	CCB cup Low Profile	1,768	77 (73-80)	55	8	4	13	29	1	2.1 (1.4-2.7)	2.6 (1.8-3.3)	2.9 (2.1-3.7)	3.2 (2.3-4.1)	4.2 (2.9-5.5)	4.7 (3.1-6.4)
Stanmore	Exceed ABT Cemented	1,273	76 (71-81)	22	4	1	8	9	0	1.0 (0.5-1.6)	1.5 (0.8-2.2)	1.8 (0.9-2.6)	3.0 (1.3-4.6)	n.a.	n.a.
C-Stem AMT	Marathon	1,133	80 (74-83)	16	0	2	0	14	0	1.2 (0.5-1.8)	1.7 (0.8-2.5)	n.a.	n.a.	n.a.	n.a.
Original ME Muller	Avantage Cemented	1,105	77 (71-82)	41	2	1	3	35	0	3.3 (2.2-4.4)	3.9 (2.6-5.1)	4.8 (3.0-6.5)	5.6 (3.2-8.0)	n.a.	n.a.
Lubinus SPII	IP Cup X-Linked	1,083	77 (72-82)	28	7	3	6	12	0	1.6 (0.9-2.4)	2.5 (1.5-3.5)	3.4 (2.1-4.7)	3.4 (2.1-4.7)	n.a.	n.a.
Stanmore	All Poly Arcom Cup	1,056*	74 (69-79)	21	3	4	13	0	1	0.3 (0.0-0.6)	1.3 (0.6-2.0)	1.7 (0.9-2.5)	1.8 (1.0-2.7)	2.7 (1.4-4.0)	n.a.
Twinsys stem Cemented	CCB cup Low Profile	884	80 (77-83)	11	1	3	6	0	1	0.5 (0.0-1.0)	1.1 (0.3-1.8)	1.5 (0.5-2.5)	1.8 (0.7-3.0)	1.8 (0.7-3.0)	n.a.
Stanmore	Muller	877*	76 (71-81)	12	3	2	6	1	0	0.7 (0.1-1.2)	1.3 (0.5-2.0)	1.3 (0.5-2.0)	1.3 (0.5-2.0)	1.7 (0.6-2.8)	n.a.
Spectron EF	Mueller cup	831*	77 (72-81)	12	3	2	4	3	0	0.4 (0.0-0.8)	0.7 (0.1-1.3)	1.0 (0.3-1.6)	1.1 (0.4-1.8)	1.4 (0.6-2.2)	1.6 (0.7-2.5)
Lubinus SPII	AVANTAGE Cemented	731	78 (72-83)	24	5	0	2	17	0	2.7 (1.5-3.9)	2.9 (1.6-4.1)	4.1 (2.2-6.0)	5.0 (2.5-7.6)	n.a.	n.a.
Spectron EF	Reflection All Poly	617*	77 (74-82)	47	11	0	32	4	0	0.8 (0.1-1.5)	1.8 (0.7-2.9)	2.7 (1.4-4.0)	3.3 (1.8-4.7)	6.6 (4.5-8.8)	10.2 (7.2-13.2)
Spectron EF	Muller low profile Durasul	503*	78 (74-83)	12	4	0	2	6	0	0.8 (0.0-1.6)	1.7 (0.5-2.8)	2.3 (0.8-3.7)	n.a.	n.a.	n.a.
MS30	Muller low profile	497*	78 (74-82)	16	0	8	8	0	0	0.8 (0.0-1.6)	1.7 (0.5-2.8)	2.4 (1.0-3.7)	3.0 (1.4-4.6)	4.5 (2.1-6.9)	n.a.
Stanmore	Apollo	381*	75 (70-79)	6	3	1	1	0	1	0.3 (0.0-0.8)	0.8 (0.0-1.7)	1.4 (0.2-2.6)	1.4 (0.2-2.6)	1.8 (0.4-3.2)	n.a.
Stanmore	Avantage Cemented	368	79 (74-84)	10	0	1	0	9	0	2.2 (0.7-3.7)	2.7 (1.1-4.4)	2.7 (1.1-4.4)	n.a.	n.a.	n.a.
Exeter	Avantage Cemented	353	74 (65-82)	8	3	2	0	3	0	1.5 (0.2-2.9)	2.5 (0.6-4.4)	3.1 (0.9-5.4)	3.1 (0.9-5.4)	n.a.	n.a.
Lubinus SPII	FAL Cup X-Linked	304	78 (74-81)	3	0	0	2	1	0	0.7 (0.0-1.8)	0.7 (0.0-1.8)	n.a.	n.a.	n.a.	n.a.
GHE-huftstiel	Huftpfanne	273*	75 (71-80)	23	5	3	15	0	0	0.4 (0.0-1.1)	1.5 (0.0-3.0)	2.7 (0.7-4.7)	4.4 (1.8-6.9)	7.2 (3.9-10.6)	n.a.
Charnley Modular	Marathon	255*	71 (65-79)	10	3	5	2	0	0	0.4 (0.0-1.2)	1.2 (0.0-2.6)	1.6 (0.0-3.2)	4.0 (1.4-6.5)	4.5 (1.8-7.3)	n.a.

* Denotes prosthesis combinations with no reported use in primary THAs in 2021.
Please note: n.a. if <50 cases were at risk; THA: total hip arthroplasty; CI: confidence interval; IQR: interquartile range.

Only combinations with over 250 procedures have been listed.
Results must be interpreted with caution. Patient characteristics like age and diagnosis, as well as procedure characteristics like the experience of the surgeon performing the procedure, femoral head size and articulation of the prosthesis may have influenced the cumulative revision percentages.

Hip » Survival » Revision per component » Uncemented primary THA – overall revision

TABLE Cumulative revision percentages of uncemented primary total hip arthroplasties by prosthesis component combination of patients who underwent a THA for osteoarthritis in the Netherlands in 2007-2021 (n=212,796)

					Type of revision (n)					Cumulative revision percentage (95% CI)
Femur component	Acetabulum component	Total primary THAs (n)	Median (IQR) age (yr)	Total RAs (n)	Total hip (complete revision)	Only femur component	Only acetabulum component	Only femoral head/inlay	Missing/ unknown	1yr	3yr	5yr	7yr	10yr	13yr
All uncemented THAs for osteoarthritis		212,796	68 (62-74)	7,307	1,198	2,568	1,909	1,511	121	1.5 (1.5-1.6)	2.5 (2.4-2.6)	3.2 (3.1-3.3)	3.8 (3.7-3.9)	4.7 (4.6-4.8)	5.7 (5.5-5.9)
Corail	Pinnacle	37,203	69 (63-75)	842	154	256	178	244	10	1.2 (1.0-1.3)	1.8 (1.7-2.0)	2.3 (2.1-2.5)	2.6 (2.4-2.8)	3.4 (3.1-3.7)	3.9 (3.4-4.4)
Taperloc Complete	Allofit	19,329	67 (61-73)	349	62	125	66	93	3	1.4 (1.2-1.6)	2.0 (1.8-2.2)	2.3 (2.0-2.6)	2.5 (2.0-2.9)	n.a.	n.a.
Alloclassic Zweymuller SL	Allofit	14,468	70 (64-76)	498	76	193	121	102	6	1.2 (1.0-1.3)	2.0 (1.8-2.2)	2.6 (2.4-2.9)	3.2 (2.8-3.5)	4.3 (3.9-4.7)	4.9 (4.4-5.4)
CLS Spotorno	Allofit	11,068	64 (58-69)	486	52	190	130	96	18	2.6 (2.3-2.9)	3.6 (3.2-3.9)	4.1 (3.7-4.4)	4.6 (4.2-5.0)	5.2 (4.7-5.7)	5.7 (5.0-6.3)
Polarstem	R3	10,103	69 (63-75)	211	20	72	24	94	1	1.8 (1.6-2.1)	2.4 (2.0-2.7)	2.7 (2.2-3.2)	n.a.	n.a.	n.a.
Taperloc Complete	Exceed ABT	8,663	69 (63-75)	192	34	70	35	49	4	1.4 (1.2-1.7)	1.9 (1.6-2.2)	2.3 (1.9-2.6)	2.6 (2.2-3.0)	2.8 (2.3-3.2)	n.a.
Accolade	Trident	7,605	69 (62-76)	311	44	161	44	60	2	1.4 (1.1-1.7)	2.8 (2.4-3.2)	3.7 (3.3-4.2)	4.4 (3.9-4.9)	5.3 (4.6-6.0)	7.6 (6.0-9.1)
Mallory Head Stems	Mallory Head	6,018	65 (60-69)	214	27	23	91	67	6	1.4 (1.1-1.7)	2.3 (1.9-2.6)	2.7 (2.3-3.1)	3.2 (2.7-3.7)	3.7 (3.2-4.2)	4.6 (3.9-5.4)
Accolade	Trident Tritanium	4,539*	68 (62-74)	120	11	44	22	42	1	1.1 (0.8-1.4)	2.2 (1.7-2.6)	2.7 (2.2-3.2)	3.1 (2.5-3.6)	n.a.	n.a.
Twinsys stem Cementless	RM Pressfit Vitamys cup	4,299	66 (60-71)	118	15	55	28	18	2	1.7 (1.3-2.1)	2.3 (1.8-2.7)	2.7 (2.2-3.2)	3.0 (2.4-3.7)	4.9 (3.7-6.2)	n.a.
Taperloc HIP system	Exceed ABT	3,892*	68 (62-75)	121	20	32	36	25	8	1.2 (0.8-1.5)	2.3 (1.8-2.8)	2.7 (2.2-3.2)	2.9 (2.4-3.5)	3.3 (2.7-3.9)	n.a.
SL Plus	Bicon Plus	3,777	70 (64-76)	260	38	131	72	16	3	1.7 (1.3-2.1)	3.9 (3.3-4.6)	5.4 (4.6-6.1)	6.3 (5.5-7.1)	7.7 (6.7-8.6)	8.7 (7.5-9.9)
Taperloc HIP system	Mallory Head	3,670*	67 (61-71)	135	26	38	48	22	1	1.5 (1.1-1.8)	2.6 (2.1-3.1)	2.9 (2.4-3.5)	3.5 (2.8-4.1)	3.8 (3.1-4.4)	4.9 (3.9-6.0)
Accolade II	Trident	3,503	70 (63-75)	60	10	21	9	19	1	1.8 (1.3-2.2)	2.4 (1.5-3.4)	2.4 (1.5-3.4)	n.a.	n.a.	n.a.
Twinsys stem Cementless	RM Pressfit cup	3,285	73 (68-78)	121	16	55	23	26	1	2.5 (2.0-3.1)	3.2 (2.5-3.8)	3.5 (2.8-4.1)	4.0 (3.2-4.7)	4.6 (3.6-5.5)	n.a.
Taperloc Complete	Mallory Head	3,105	67 (61-72)	114	20	25	30	38	1	2.1 (1.6-2.6)	3.1 (2.5-3.7)	3.4 (2.7-4.0)	3.8 (3.1-4.5)	5.0 (3.5-6.5)	n.a.
Synergy	Reflection	2,930*	66 (60-72)	139	11	67	29	31	1	2.1 (1.6-2.6)	2.7 (2.1-3.3)	3.1 (2.5-3.7)	3.6 (2.9-4.3)	4.5 (3.7-5.3)	6.2 (5.1-7.3)
Alloclassic Zweymuller SL	Alloclassic Zweymuller CSF	2,903*	69 (63-75)	127	16	50	24	35	2	1.1 (0.7-1.5)	2.7 (2.1-3.2)	3.3 (2.6-3.9)	3.5 (2.9-4.2)	4.4 (3.6-5.2)	4.9 (4.0-5.8)
Alloclassic offset	Allofit	2,770	71 (65-77)	80	16	32	15	14	3	1.3 (0.9-1.7)	2.0 (1.4-2.5)	2.6 (1.9-3.2)	2.9 (2.2-3.6)	3.6 (2.8-4.5)	4.1 (3.1-5.2)
M/L Taper	Allofit IT	2,144	71 (65-76)	74	10	29	24	10	1	2.3 (1.6-2.9)	3.2 (2.4-4.0)	3.7 (2.8-4.5)	4.0 (3.1-5.0)	4.3 (3.2-5.3)	n.a.
Synergy	R3	2,096	66 (60-72)	62	10	34	8	8	2	1.8 (1.2-2.4)	2.3 (1.7-3.0)	2.8 (2.1-3.5)	3.1 (2.3-3.9)	3.2 (2.4-4.0)	n.a.
SYMAX	Trident	2,073*	69 (63-75)	71	6	18	20	27	0	0.6 (0.3-0.9)	1.7 (1.1-2.2)	2.2 (1.5-2.8)	2.8 (2.0-3.5)	3.2 (2.5-4.0)	4.0 (3.1-5.0)
Anthology	R3	1,841	65 (59-69)	59	8	20	16	15	0	2.1 (1.4-2.7)	2.6 (1.9-3.3)	3.4 (2.5-4.2)	3.6 (2.7-4.5)	3.6 (2.7-4.5)	n.a.
SYMAX	Trident Tritanium	1,743*	67 (61-73)	85	10	37	24	13	1	2.3 (1.6-3.0)	3.6 (2.7-4.5)	4.0 (3.0-4.9)	4.6 (3.6-5.6)	5.4 (4.2-6.6)	n.a.
Corail AMT	Pinnacle	1,683	69 (62-74)	16	2	5	4	5	0	0.7 (0.3-1.1)	1.2 (0.5-1.8)	n.a.	n.a.	n.a.	n.a.

TABLE Continued – Cumulative revision percentages of uncemented primary total hip arthroplasties by prosthesis component combination of patients who underwent a THA for osteoarthritis in the Netherlands in 2007-2021 (n=212,796)

					Type of revision (n)					Cumulative revision percentage (95% CI)
Femur component	Acetabulum component	Total primary THAs (n)	Median (IQR) age (yr)	Total RAs (n)	Total hip (complete revision)	Only femur component	Only acetabulum component	Only femoral head/inlay	Missing/ unknown	1yr	3yr	5yr	7yr	10yr	13yr
Mallory Head Stems	Exceed ABT	1,637*	65 (59-71)	36	3	15	16	2	0	0.7 (0.3-1.1)	1.6 (1.0-2.2)	1.7 (1.0-2.3)	2.0 (1.3-2.7)	2.4 (1.6-3.2)	n.a.
OMNIFIT HA	Trident	1,501*	63 (57-67)	145	18	70	24	29	4	3.1 (2.2-3.9)	4.5 (3.4-5.5)	6.3 (5.0-7.5)	7.8 (6.4-9.1)	9.5 (8.0-11.0)	10.5 (8.8-12.2)
M/L Taper	Continuum	1,265	68 (63-73)	22	2	17	2	1	0	1.5 (0.8-2.2)	1.9 (1.1-2.7)	1.9 (1.1-2.7)	n.a.	n.a.	n.a.
Alloclassic Zweymuller SL	Continuum	1,207	71 (64-77)	31	7	12	4	7	1	1.3 (0.7-2.0)	2.0 (1.2-2.8)	2.4 (1.5-3.3)	2.6 (1.7-3.6)	n.a.	n.a.
Taperloc Complete	G7 PPS	1,199	69 (63-75)	22	6	9	4	3	0	2.3 (1.3-3.3)	n.a.	n.a.	n.a.	n.a.	n.a.
Fitmore	Allofit	1,187	67 (62-72)	13	3	3	1	6	0	1.0 (0.4-1.6)	n.a.	n.a.	n.a.	n.a.	n.a.
CLS Spotorno	RM Classic cup	1,178*	63 (58-68)	75	14	21	32	7	1	1.9 (1.1-2.6)	2.6 (1.7-3.6)	3.3 (2.3-4.4)	3.9 (2.8-5.0)	5.1 (3.8-6.4)	6.6 (5.1-8.1)
CLS Spotorno	Pinnacle	1,166*	67 (62-72)	50	7	17	10	16	0	1.3 (0.6-1.9)	2.3 (1.4-3.1)	2.8 (1.9-3.8)	3.6 (2.5-4.8)	5.2 (3.7-6.7)	n.a.
SL Plus Mia	R3	1,109*	71 (65-77)	33	3	16	6	8	0	1.9 (1.1-2.7)	2.7 (1.8-3.7)	3.1 (2.0-4.1)	3.1 (2.0-4.1)	3.1 (2.0-4.1)	n.a.
SL Plus	Reflection	1,020*	67 (61-73)	42	5	14	14	9	0	1.8 (1.0-2.6)	3.3 (2.2-4.4)	3.8 (2.6-5.0)	4.4 (3.1-5.7)	4.4 (3.1-5.7)	n.a.
Avenir Muller	Allofit	1,006	69 (62-73)	16	2	7	2	5	0	1.3 (0.6-2.0)	1.4 (0.6-2.2)	1.7 (0.8-2.6)	2.2 (1.0-3.4)	2.2 (1.0-3.4)	n.a.
SL Plus	Hofer-Imhoff Lubrimet	977*	70 (64-76)	57	13	27	9	6	2	1.1 (0.5-1.8)	2.3 (1.3-3.2)	3.6 (2.4-4.7)	4.5 (3.1-5.8)	5.6 (4.1-7.1)	6.7 (4.8-8.5)
Alloclassic Zweymuller SL	Trilogy	968*	68 (63-75)	35	10	10	7	8	0	1.3 (0.6-2.1)	2.2 (1.3-3.1)	2.6 (1.6-3.6)	2.9 (1.9-4.0)	3.6 (2.4-4.8)	3.7 (2.5-5.0)
Polarstem	Reflection	927*	70 (64-76)	18	5	4	2	7	0	1.1 (0.4-1.7)	1.6 (0.8-2.4)	2.2 (1.2-3.3)	2.2 (1.2-3.3)	n.a.	n.a.
Summit Tapered	Pinnacle Gription	880	68 (62-73)	19	2	5	2	9	1	1.9 (1.0-2.8)	2.2 (1.2-3.2)	2.6 (1.3-3.8)	n.a.	n.a.	n.a.
SL Plus	EP-Fit Plus	790*	68 (63-75)	45	10	24	10	1	0	1.3 (0.5-2.1)	3.1 (1.9-4.3)	3.8 (2.4-5.1)	4.9 (3.3-6.4)	5.7 (4.0-7.4)	6.5 (4.6-8.3)
Alloclassic Zweymuller SL	Alloclassic Variall	778*	71 (64-77)	23	4	10	3	5	1	1.0 (0.3-1.7)	1.9 (1.0-2.9)	2.4 (1.3-3.4)	2.6 (1.5-3.8)	3.0 (1.7-4.2)	3.5 (1.9-5.1)
CLS Spotorno	Fitmore	758*	66 (61-71)	36	3	16	6	10	1	1.9 (0.9-2.8)	2.4 (1.3-3.5)	2.6 (1.5-3.8)	3.3 (2.0-4.6)	4.4 (2.9-5.9)	5.2 (3.5-6.9)
DB10	Spidercup	755*	71 (64-77)	39	2	19	10	7	1	1.5 (0.6-2.3)	2.3 (1.2-3.3)	2.9 (1.6-4.1)	3.7 (2.4-5.1)	5.0 (3.3-6.7)	7.2 (4.6-9.7)
Taperloc Complete	Continuum	751	68 (59-74)	15	4	5	1	5	0	1.9 (0.9-2.9)	2.7 (0.9-4.4)	n.a.	n.a.	n.a.	n.a.
CLS Spotorno	Morscher	712*	73 (68-78)	37	6	19	12	0	0	1.3 (0.4-2.1)	2.6 (1.4-3.7)	3.2 (1.9-4.5)	4.2 (2.7-5.7)	5.9 (3.9-7.8)	7.8 (4.5-11.1)
Optimys stem	RM Pressfit Vitamys cup	677	62 (55-68)	14	2	9	2	1	0	2.0 (0.9-3.1)	2.4 (1.1-3.7)	2.4 (1.1-3.7)	n.a.	n.a.	n.a.
CLS Spotorno	RM Pressfit cup	625*	66 (60-71)	52	5	21	18	5	3	3.1 (1.7-4.4)	4.4 (2.8-6.0)	5.7 (3.9-7.6)	6.5 (4.5-8.5)	7.8 (5.6-10.0)	9.8 (7.2-12.4)
CBH stem	RM Pressfit Vitamys cup	593*	65 (60-70)	24	8	7	7	2	0	1.0 (0.2-1.8)	2.4 (1.1-3.6)	3.3 (1.8-4.7)	4.0 (2.4-5.6)	n.a.	n.a.
CBH stem	RM Pressfit cup	551*	75 (69-79)	23	4	6	11	2	0	2.2 (1.0-3.4)	3.7 (2.1-5.3)	3.9 (2.3-5.5)	4.3 (2.6-6.1)	n.a.	n.a.
Alloclassic Zweymuller SL	Trabecular Metal	547*	68 (62-75)	25	2	7	9	6	1	0.6 (0.0-1.2)	1.9 (0.7-3.0)	2.6 (1.3-4.0)	3.2 (1.7-4.7)	3.4 (1.8-4.9)	4.8 (2.8-6.8)

Only combinations with over 500 procedures have been listed.
Results must be interpreted with caution. Patient characteristics like age and diagnosis, as well as procedure characteristics like the experience of the surgeon performing the procedure, femoral head size and articulation of the prosthesis may have influenced the cumulative revision percentages.

Hip » Survival » Revision per component » Cemented primary THA – major revision

TABLE Cumulative major revision percentages of the most frequently used cemented primary total hip arthroplasties by prosthesis component combination of patients who underwent a THA for osteoarthritis in the Netherlands in 2007-2021 (n=82,092)

					Cumulative revision percentage Kaplan Meier (95% CI)
Femur component	Acetabulum component	Total primary THAs (n)	Median (IQR) age (yr)	Major revision¹ arthroplasties (n)	1yr	3yr	5yr	7yr	10yr	13yr
All cemented THAs for osteoarthritis		82,092	76 (71-81)	1,755	0.7 (0.6-0.7)	1.4 (1.3-1.4)	1.8 (1.7-1.9)	2.3 (2.2-2.4)	3.0 (2.8-3.1)	3.8 (3.6-4.1)
Lubinus SPII	IP Cup	14,118	76 (72-81)	287	0.6 (0.4-0.7)	1.4 (1.2-1.6)	1.9 (1.7-2.2)	2.2 (1.9-2.5)	2.7 (2.3-3.0)	3.7 (3.0-4.3)
Original ME Muller	Muller low profile Durasul	8,498	75 (70-80)	94	0.5 (0.4-0.7)	0.9 (0.6-1.1	1.2 (0.9-1.5)	1.4 (1.1-1.7)	1.8 (1.4-2.2)	1.8 (1.4-2.2)
Original ME Muller	Muller low profile	6,324	77 (73-81)	136	0.9 (0.7-1.1)	1.8 (1.4-2.1)	2.1 (1.7-2.4)	2.4 (2.0-2.8)	2.4 (2.0-2.8)	2.7 (2.1-3.2)
Lubinus SPII	FAL Cup	5,760	75 (70-80)	133	1.0 (0.7-1.2)	1.6 (1.3-2.0)	2.3 (1.8-2.7)	2.9 (2.4-3.5)	3.6 (2.9-4.3)	4.0 (3.1-5.0)
Spectron EF	Reflection All Poly XLPE	4,878	77 (73-81)	92	0.4 (0.2-0.5)	1.1 (0.8-1.3)	1.5 (1.1-1.8)	2.1 (1.7-2.6)	2.4 (1.9-2.9)	2.6 (2.0-3.1)
Exeter	Exeter Rimfit X3	4,664	75 (69-80)	66	0.7 (0.5-0.9)	1.2 (0.9-1.6)	1.7 (1.3-2.1)	1.7 (1.3-2.1)	1.8 (1.3-2.3)	n.a.
Stanmore	Stanmore	3,374	75 (70-80)	67	0.5 (0.3-0.8)	1.3 (0.9-1.7)	1.7 (1.2-2.1)	1.9 (1.4-2.3)	2.3 (1.7-2.9)	2.5 (1.8-3.2)
Exeter	Exeter Contemporary Hooded	2,827*	77 (72-81)	81	0.7 (0.4-1.0)	1.2 (0.8-1.6)	1.8 (1.3-2.3)	2.3 (1.7-2.9)	3.8 (2.9-4.7)	4.3 (3.2-5.3)
Lubinus SPII	SHP	2,506*	75 (71-80)	44	0.2 (0.0-0.4)	0.6 (0.3-0.9)	0.9 (0.5-1.3)	1.7 (1.1-2.2)	1.9 (1.4-2.5)	2.0 (1.4-2.6)
Exeter	Exeter	2,447*	73 (68-79)	115	1.8 (1.2-2.3)	2.5 (1.9-3.1)	3.1 (2.4-3.8)	3.8 (3.0-4.6)	5.1 (4.1-6.1)	5.8 (4.7-6.9)

¹ Revision of at least the acetabulum or femur component.
* Denotes prosthesis combinations with no reported use in primary THAs in 2021.
Please note: n.a. if <50 cases were at risk; THA: total hip arthroplasty; CI: confidence interval; IQR: interquartile range.

Results must be interpreted with caution. Patient characteristics like age and diagnosis, as well as procedure characteristics like the experience of the surgeon performing the procedure, femoral head size and articulation of the prosthesis may have influenced the cumulative revision percentages.

Hip » Survival » Revision per component » Uncemented primary THA – major revision

TABLE Cumulative major revision percentages of the most frequently used uncemented primary total hip arthroplasties by prosthesis component combination of patients who underwent a THA for osteoarthritis in the Netherlands in 2007-2021 (n=212,796)

					Cumulative revision percentage (95% CI)
Femur component	Acetabulum component	Total primary THAs (n)	Median (IQR) age (yr)	Major revision¹ arthroplasties (n)	1yr	3yr	5yr	7yr	10yr	13 yr
All uncemented THAs for osteoarthritis		212,796	68 (62-74)	5,936	1.1 (1.1-1.1)	2.0 (1.9-2.0)	2.6 (2.5-2.6)	3.1 (3.0-3.2)	3.9 (3.8-4.0)	4.9 (4.7-5.0)
Corail	Pinnacle	37,202	69 (63-75)	632	0.7 (0.7-0.8)	1.3 (1.3-1.4)	1.8 (1.8-1.9)	2.0 (2.0-2.2)	2.7 (2.7-2.9)	3.1 (3.1-3.6)
Taperloc Complete	Allofit	19,329	67 (61-73)	267	1.0 (1.0-1.2)	1.6 (1.6-1.8)	1.9 (1.9-2.1)	2.0 (2.0-2.4)	2.0 (2.0-2.4)	2.0 (2.0-2.4)
Alloclassic Zweymuller SL	Allofit	14,468	70 (64-76)	405	0.9 (0.9-1.0)	1.6 (1.6-1.8)	2.1 (2.1-2.4)	2.5 (2.5-2.8)	3.5 (3.5-3.8)	4.1 (4.1-4.6)
CLS Spotorno	Allofit	11,068	64 (58-69)	395	1.9 (1.9-2.1)	2.8 (2.8-3.1)	3.2 (3.2-3.6)	3.8 (3.8-4.1)	4.4 (4.4-4.9)	4.8 (4.8-5.5)
Polarstem	R3	10,103	69 (63-75)	125	1.0 (1.0-1.2)	1.5 (1.5-1.7)	1.8 (1.8-2.3)	n.a.	n.a.	n.a.
Taperloc Complete	Exceed ABT	8,663	69 (63-75)	147	1.1 (1.1-1.3)	1.5 (1.5-1.7)	1.7 (1.7-2.0)	2.0 (2.0-2.4)	2.2 (2.2-2.6)	n.a.
Accolade	Trident	7,605	69 (62-76)	260	1.0 (1.0-1.3)	2.2 (2.2-2.6)	3.1 (3.1-3.5)	3.6 (3.6-4.1)	4.6 (4.6-5.2)	7.0 (7.0-8.6)
Mallory Head Stems	Mallory Head	6,018	65 (60-69)	156	0.9 (0.9-1.2)	1.6 (1.6-1.9)	2.0 (2.0-2.4)	2.4 (2.4-2.8)	2.8 (2.8-3.2)	3.3 (3.3-4.0)
Accolade	Trident Tritanium	4,539*	68 (62-74)	78	0.6 (0.6-0.8)	1.4 (1.4-1.8)	1.8 (1.8-2.2)	2.0 (2.0-2.5)	n.a.	n.a.
Twinsys stem Cementless	RM Pressfit Vitamys cup	4,299	66 (60-71)	102	1.4 (1.4-1.7)	1.9 (1.9-2.3)	2.3 (2.3-2.8)	2.7 (2.7-3.3)	4.4 (4.4-5.6)	n.a.

¹ Revision of at least the acetabulum or femur component.
Please note: n.a. if <50 cases were at risk; THA: total hip arthroplasty; CI: confidence interval; IQR: interquartile range.

Results must be interpreted with caution. Patient characteristics like age and diagnosis, as well as procedure characteristics like the experience of the surgeon performing the procedure, femoral head size and articulation of the prosthesis may have influenced the cumulative revision percentages.

Hip » Survival » Revision per component » Bone cement THA

TABLE Cumulative revision percentages of the most frequently types of bone cement by type of mixing system in primary total hip arthroplasties in the Netherlands in 2007-2021

			Cumulative revision percentage Kaplan Meier (95% CI)
Bone cement	Total primary THAs (n)	Total RAs (n)	1yr	3yr	5yr	7yr	10yr	13yr
Separately packed bone cement components	90,412	3,081	1.4 (1.4-1.5)	2.4 (2.3-2.5)	3.0 (2.9-3.1)	3.5 (3.4-3.6)	4.3 (4.2-4.5)	5.3 (5.0-5.6)
Palacos R+G	69,263	2,283	1.5 (1.4-1.6)	2.5 (2.3-2.6)	3.0 (2.9-3.2)	3.5 (3.3-3.6)	4.2 (4.0-4.4)	5.2 (4.8-5.5)
Refobacin Bone Cement R	6,178	182	1.0 (0.8-1.3)	1.9 (1.6-2.3)	2.3 (1.9-2.7)	2.8 (2.4-3.3)	3.7 (3.1-4.2)	3.8 (3.2-4.4)
Palacos MV+G	3,720	93	0.9 (0.6-1.2)	1.4 (1.0-1.8)	2.1 (1.6-2.6)	3.1 (2.5-3.8)	3.5 (2.8-4.3)	n.a.
Simplex ABC EC	2,670	146	2.2 (1.6-2.7)	3.5 (2.8-4.2)	4.4 (3.6-5.2)	5.1 (4.2-6.0)	6.7 (5.5-7.9)	9.0 (6.8-11.3)
Simplex ABC Tobra	2,304	143	2.0 (1.4-2.6)	3.3 (2.5-4.0)	4.0 (3.2-4.8)	4.7 (3.8-5.6)	6.5 (5.4-7.6)	7.6 (6.3-8.9)
Simplex P	1,321*	29	0.8 (0.3-1.2)	1.8 (1.1-2.5)	1.9 (1.1-2.6)	2.1 (1.3-2.9)	2.7 (1.7-3.8)	2.7 (1.7-3.8)
Simplex HV	572*	12	0.7 (0.0-1.4)	0.9 (0.1-1.7)	2.1 (0.9-3.3)	2.6 (1.0-4.2)	n.a.	n.a.
Refobacin Plus Bone Cement	557*	22	1.6 (0.6-2.7)	2.6 (1.2-3.9)	3.4 (1.8-4.9)	3.7 (2.0-5.3)	4.3 (2.5-6.2)	4.8 (2.7-6.9)
Palamed G	493*	14	0.4 (0.0-1.0)	0.8 (0.0-1.6)	1.3 (0.3-2.3)	2.0 (0.7-3.2)	3.0 (1.4-4.6)	3.3 (1.6-4.9)
Biomet Plus Bone Cement	453*	26	0.4 (0.0-1.1)	1.4 (0.3-2.4)	2.5 (1.1-4.0)	3.3 (1.6-5.0)	4.4 (2.4-6.3)	7.4 (4.5-10.3)
Subiton G	381	6	0.9 (0.0-2.0)	2.5 (0.4-4.5)	n.a.	n.a.	n.a.	n.a.
CMW 1 Gentamicin Bone Cement	326*	13	1.9 (0.4-3.3)	2.8 (1.0-4.6)	3.1 (1.2-5.0)	3.1 (1.2-5.0)	4.0 (1.7-6.2)	4.5 (2.1-6.8)
Palacos R	312	16	1.6 (0.2-3.0)	2.7 (0.8-4.5)	4.2 (1.9-6.5)	5.0 (2.4-7.6)	6.2 (3.2-9.3)	n.a.
Palamed	277*	22	1.1 (0.0-2.3)	2.5 (0.7-4.4)	3.7 (1.4-5.9)	3.7 (1.4-5.9)	6.1 (3.2-9.0)	8.9 (5.3-12.4)
Bone cement pre-packed in a vacuum mixing system	31,948	902	1.9 (1.8-2.1)	2.7 (2.5-2.9)	3.3 (3.0-3.5)	3.8 (3.5-4.1)	4.6 (4.1-5.2)	5.1 (4.3-5.8)
Refobacin Bone Cement R	15,726	469	2.0 (1.8-2.2)	2.8 (2.5-3.0)	3.3 (3.0-3.7)	3.9 (3.5-4.3)	5.2 (4.2-6.1)	n.a.
Palacos R+G	11,237	297	2.1 (1.8-2.3)	2.9 (2.5-3.2)	3.6 (3.1-4.0)	n.a.	n.a.	n.a.
Refobacin Plus Bone Cement	4,296	114	1.3 (0.9-1.6)	2.1 (1.7-2.6)	2.6 (2.1-3.1)	3.1 (2.5-3.7)	3.4 (2.7-4.1)	n.a.
Cemex Genta	429	10	1.2 (0.2-2.2)	1.9 (0.6-3.2)	2.2 (0.8-3.6)	2.2 (0.8-3.6)	3.8 (0.4-7.2)	n.a.

* Denotes types of bone cement with no reported use in primary THAs in 2021.
Please note: n.a. if <50 cases were at risk; THA: total hip arthroplasty; CI: confidence interval; IQR: interquartile range.

Only types of bone cement with over 250 procedures have been listed.
Results must be interpreted with caution. Patient characteristics like age and diagnosis, as well as procedure characteristics like the experience of the surgeon performing the procedure, femoral head size and articulation of the prosthesis may have influenced the cumulative revision percentages.

Hip » Survival » Revision per component » THA by ODEP 5A or higher acetabulum

ODEP rating
Orthopaedic Data Evaluation Panel. ODEP provides ratings for hip femoral stems, hip acetabular cups and total knee replacement implants. An ODEP rating consists of a number and a letter (A or B), and a star (optional). The number represents the number of years for which the product’s performance had been evidenced. The letter represents the strength of evidence presented by the manufacturer (A represents strong evidence and B represents acceptable evidence). A Star (*) represents very strong evidence above A and B. Detailed information can be found at www.odep.org.uk

FIGURE Cumulative acetabulum revision percentage of total hip arthroplasties by ODEP rating acetabulum in the Netherlands in 2007-2021 (n= 376,606)

TABLE Cumulative 13-year acetabulum revision percentage

		Cumulative 13-year acetabulum revision percentage
	Number (n)	Competing Risk¹ (95% CI)	Kaplan Meier (95% CI)
ODEP acetabulum
<5A	20,452	5.9 (5.5-6.3)	7.0 (6.5-7.4)
5A or higher	356,154	2.4 (2.3-2.5)	3.0 (2.9-3.1)

¹ The cumulative revision percentage using the competing risk method is shown in the figure.
Acetabulum revision percentage: first revision of the acetabulum component, regardless of whether a minor revision has already taken place. Therefor, the first three revision procedures were reviewed.
ODEP rating: ODEP provides ratings for hip femoral stems, hip acetabular cups and total knee replacement implants. Detailed information can be found at www.odep.org.uk.
Please note: Dotted lines represent the upper and lower limits of the 95% confidence interval.
THA: total hip arthroplasty; CI: confidence interval.

Hip » Survival » Revision per component » THA by ODEP 5A or higher femur

This website is only accessable on large screens